Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 14:12:9697-9706.
doi: 10.2147/OTT.S209757. eCollection 2019.

IP10-CDR3 Reduces The Viability And Induces The Apoptosis Of Ovarian Cancer Cells By Down-Regulating The Expression Of Bcl-2 And Caspase 3

Affiliations

IP10-CDR3 Reduces The Viability And Induces The Apoptosis Of Ovarian Cancer Cells By Down-Regulating The Expression Of Bcl-2 And Caspase 3

Qi Chen et al. Onco Targets Ther. .

Abstract

Purpose: This study aimed to explore the effects of interferon-γ inducible protein 10 (IP10) and complementarity-determining region 3 (CDR3) of T cells receptor on ovarian cancer cells and the involved mechanisms.

Methods: IP10 and CDR3 were linked with single-chain antibody (scfv) and exotoxin gene muton of Pseudomonas aeruginosa (PE40) to construct IP10-CDR3scfv and IP10-CDR3-PE40scfv. Then, we constructed pcDNA3.1-IP10-CDR3scfv and pcDNA3.1-IP10-CDR3-PE40scfv plasmids which were proved by HindIII/EcoRI digestion. SKOV3 cells and HOSEpiC cells were incubated with fluorescein isothiocyanate (FITC) labeled IP10-CDR3scfv and IP10-CDR3-PE40scfv proteins and protein levels were examined by flow cytometry. After gene transfection, SKOV3 cells were divided into four groups: Control, pcDNA3.1(+) negative control (NC) (pcDNA3.1(+) NC transfection), IP10-CDR3scfv (IP10-CDR3scfv transfection) and IP10-CDR3-PE40scfv (IP10-CDR3-PE40scfv transfection). Levels of IP10, CDR3, Caspase-3, cleaved Caspase-3 and Bcl-2 were determined by RT-PCR and Western blot. Cell viability and apoptosis were investigated by CCK-8 assay and Annexin V-FITC/PI assay, respectively.

Results: The levels of FITC-labeled IP10-CDR3scfv and IP10-CDR3-PE40scfv proteins in the SKOV3+IP10-CDR3scfv group and the SKOV3+IP10-CDR3-PE40scfv group were remarkably higher than that in the SKOV3 group (P<0.05). So was the HOSEpiC related groups. There was no obvious difference in the levels of IP10, CDR3, Caspase-3, cleaved Caspase-3 and Bcl-2 between the control group and the pcDNA3.1(+) NC group. However, compared with the control group, the levels of Caspase-3 and Bcl-2 were reduced notably and the levels of IP10, CDR3 and cleaved Caspase-3 were elevated sharply in the IP10-CDR3scfv and IP10-CDR3-PE40scfv groups (P<0.05). The control group and the pcDNA3.1(+) NC group demonstrated similar cell viability and apoptosis. However, compared with the control group, cell viability in the IP10-CDR3scfv and IP10-CDR3-PE40scfv groups decreased significantly and cell apoptosis increased (P<0.05).

Conclusion: IP10-CDR3 could reduce the viability and induce the apoptosis of ovarian cancer cells by down-regulating the expression of Bcl-2 and Caspase-3.

Keywords: Bcl-2; CDR3; Caspase-3; IP10; cell apoptosis; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Electrophorograms of pcDNA3.1-IP10-CDR3scfv (A) and pcDNA3.1-IP10-CDR3-PE40scfv (B) plasmids. Lane 1: pcDNA3.1-IP10-CDR3scfv plasmid or pcDNA3.1-IP10-CDR3-PE40scfv plasmid; Lane 2: pcDNA3.1-IP10-CDR3scfv plasmid or pcDNA3.1-IP10-CDR3-PE40scfv plasmid digested by HindIII/EcoRI. Abbreviation: M, marker.
Figure 2
Figure 2
The protein levels after FITC-labeled IP10-CDR3scfv protein and FITC-labeled IP10-CDR3-PE40scfv protein were added to SKOV3 cells and HOSEpiC cells for 48 hrs which were determined by flow cytometry. *P<0.05 vs. SKOV3 or HOSEpiC; #P<0.05 vs. SKOV3+IP10-CDR3scfv or HOSEpiC+IP10-CDR3scfv.
Figure 3
Figure 3
The mRNA levels of IP10, CDR3, Caspase-3 and Bcl-2 in SKOV3 cells of various groups which were determined by RT-PCR. *P<0.05 vs. Control; #P<0.05 vs. IP10-CDR3scfv. Control: without any transfection; NC: pcDNA3.1(+) negative control transfection.
Figure 4
Figure 4
The protein levels of Caspase-3, Bcl-2 (A) and cleaved Caspase-3 (B) in SKOV3 cells of various groups which were evaluated by Western blot. *P<0.05 vs. Control. Control: without any transfection; NC: pcDNA3.1(+) negative control transfection.
Figure 5
Figure 5
The viability of SKOV3 cells in various groups which was expressed as absorbance and examined by CCK-8 assay. *P<0.05 vs. Control; #P<0.05 vs. IP10-CDR3scfv. Control: without any transfection; NC: pcDNA3.1(+) negative control transfection.
Figure 6
Figure 6
The apoptosis of SKOV3 cells in various groups which was assessed by Annexin V-FITC/PI assay. *P<0.05 vs Control; #P<0.05 vs IP10-CDR3scfv. Control: without any transfection; NC: pcDNA3.1(+) negative control transfection.

Similar articles

Cited by

References

    1. Crane EK, Brown J. Early stage mucinous ovarian cancer: a review. Gynecol Oncol. 2018;149:598–604. doi:10.1016/j.ygyno.2018.01.035 - DOI - PubMed
    1. Qin M, Jin Y, Ma L, et al. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. Oncotarget. 2018;9:8614–8628. doi:10.18632/oncotarget.v9i9 - DOI - PMC - PubMed
    1. Vetter MH, Hays JL. Use of targeted therapeutics in epithelial ovarian cancer: a review of current literature and future directions. Clin Ther. 2018;40:361–371. doi:10.1016/j.clinthera.2018.01.012 - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.v68.6 - DOI - PubMed
    1. Alipour S, Zoghi S, Khalili N, et al. Specific immunotherapy in ovarian cancer: a systematic review. Immunotherapy. 2016;8:1193–1204. doi:10.2217/imt-2016-0034 - DOI - PubMed